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Abstract
Increasing evidence that decreased bone density and increased rates of bone fracture are associated with abnormal
metabolic states such as hyperglycemia and insulin resistance indicates that diabetes is a risk factor for osteoporosis. In this
study, we observed that TallyHo/JngJ (TH) mice, a polygenic model of type II diabetes, spontaneously developed bone
deformities with osteoporotic features. Female and male TH mice significantly gained more body weight than control
C57BL/6 mice upon aging. Interestingly, bone density was considerably decreased in male TH mice, which displayed
hyperglycemia. The osteoblast-specific bone forming markers osteocalcin and osteoprotegerin were decreased in TH mice,
whereas osteoclast-driven bone resorption markers such as IL-6 and RANKL were significantly elevated in the bone marrow
and blood of TH mice. In addition, RANKL expression was prominently increased in CD4+ T cells of TH mice upon T cell
receptor stimulation, which was in accordance with enhanced IL-17 production. IL-17 production in CD4+ T cells was
directly promoted by treatment with leptin while IFN-c production was not. Moreover, blockade of IFN-c further increased
RANKL expression and IL-17 production in TH-CD4+ T cells. In addition, the osteoporotic phenotype of TH mice was
improved by treatment with alendronate. These results strongly indicate that increased leptin in TH mice may act in
conjunction with IL-6 to preferentially stimulate IL-17 production in CD4+ T cells and induce RANKL-mediated
osteoclastogenesis. Accordingly, we propose that TH mice could constitute a beneficial model for osteoporosis.
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Introduction
Bone tissue continuously undergoes remodeling through
mechanical coupling of osteoclastic bone resorption and osteo-
blastic bone formation. Bone homeostasis is controlled by a
variety of soluble factors such as growth factors, hormones, and
cytokines. For example, insulin-like growth factor (IGF), trans-
forming growth factor (TGF) and parathyroid hormone (PTH)
stimulate the production of bone collagen and matrix proteins in
osteoblasts and increase osteoclast apoptosis, thus resulting in
increased bone formation [1–6]. On the other hand, inflamma-
tory cytokines, including IL-1, IL-6, and TNF-a,e n h a n c e
osteoclastic bone resorption, further inducing bone destruction
[7–10]. Osteoclast activity is directly stimulated by osteoblasts
through the interaction of receptor activator of NF-kB( R A N K )
with RANK ligand (RANKL) [11], whereas osteoprotegerin
(OPG), a decoy RANKL receptor produced by osteoblasts,
inhibits osteoclast differentiation and activity [12,13]. RANKL is
expressed not only in osteoblasts but also in activated CD4+ T
cells [14–16] and is increased by IL-1b or TNF-a in combination
with IL-17 [17]. Other cytokines produced by T cells such as IL-4,
IL-13, IFN-c, and TGF-b induce OPG expression and interfere
with the RANKL-RANK signaling pathway, thus suppressing
osteoclastogenesis [18,19].
Bone functions as an endocrine organby producing bone hormone
osteocalcin (OCN) [20]. Osteoblast-specific OCN is a hormone that
increases insulin production and sensitivity,promotingglucose uptake
and energy metabolism [21]. OCN deficiency reduces b-cell
proliferation and insulin secretion, mediating insulin resistance [22].
Moreover, OCN functions in vitro on pancreatic b-islet cells to
stimulate insulin production and secretion and on muscle to increase
insulin-mediated glucose uptake [20]. Moreover, OCN modulates
theexpressionofadiponectin and leptinin adipocytes,suggestingthat
it may control an intimate link between bone and fat [23]. Recent
findings that OCN expression is associated positively with insulin
sensitivity [24–26], as well as the observation that decreased bone
density and increased fracture risk are closely associated with diabetes
[27–30], strongly support the notion that bone homeostasis is affected
by insulin insufficiency or resistance under diabetic conditions.
Consistently, hyperglycemic and hyperleptinemic conditions are
identified as osteoporotic risk factors. However, the molecular links
between these risk factors and osteoporosis remain largely unchar-
acterized.
In this study, we observed that TH mice, a polygenic diabetes
model, displayed severe osteoporotic phenotypes with male pre-
dominance and intended to uncover the molecular links between
inflammatory factors and osteoporosis in TH mice. Whereas bone
mineral density (BMD) and OCN were significantly decreased in TH
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were considerably elevated. In addition, we observed that RANKL
expression was increased in CD4+ Tc e l l so fT Hm i c ea n dt h a t
blockade of IFN-c and leptin further increased IL-17 production in
CD4+ T cells. These results suggest that TH mice displaying bone
loss as well as increased levels of IL-17 and RANKL in T cells due to
hyperleptinemia may be an effective animal model for osteoporosis
secondary to diabetes in males.
Materials and Methods
Ethics Statement
All animal studies were conducted in accordance with IACUC
guidelines and were approved by the IACUC committee at Ewha
Womans University (ELAGC-05-1007 and IACUC 2010-13-1).
Animals
C57BL/6 (B6) and TallyHo/JngJ (TH) mice were purchased
from Jackson Laboratory (Bar Harbor, ME, USA) and housed
under specific pathogen-free conditions.
Isolation and activation of CD4+ T cells
Single cell suspensions were obtained from the lymph nodes
(LN) of B6 and TH mice and incubated with magnetic beads
coated with anti-mouse CD4 Ab (Miltenyi Biotech, Auburn, CA,
USA). CD4+ T cells were isolated according to the manufacturer’s
instructions and stimulated with anti-CD3 (1 mg/ml, BD Phar-
mingen, San Jose, CA, USA) and anti-CD28 (1 mg/ml, BD
Pharmingen) Abs in the presence of recombinant human IL-2
(10 U/ml, BD Pharmingen) for 24 h or 48 h.
Assessment of bone microarchitecture and measurement
of BMD and BMC
B6 and TH mice were analyzed by high-resolution micro-
computed tomography (micro-CT, Explore Locus Scanner, GE
Healthcare, Ontario, Canada) with an 80 kV energy source, 450 mA
current, 400 ms exposure time, and 46 mm pixel size. Approximately
400 projections were acquired over a rotation range of 180 degrees,
with a rotation step of 1 degree. The femur was scanned at pixel size
of 0.046 mm. The three-dimensional bone images were reconstituted
Figure 1. Increased bone loss in male TH mice. (A) Body weights of B6 and TH mice were measured every week from an age of 4 weeks to an
age of 20 weeks. The mean values of body weight (n=6) are presented for both males and females. (B) BMD was determined in males and females at
the indicated ages using micro-CT and microView and is expressed as mean 6 SEM (n=7). (C) Three-dimensional micro-CT images of femur and
trabecular bone were collected by using a micro-CT scanner and one representative image is shown. (D) Whole femur BMC was analyzed using high-
resolution micro-CT, and the result given as the mean 6 SEM for seven mice.
doi:10.1371/journal.pone.0018168.g001
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view image processing software (MicroView v2.2, GE Healthcare).
In vitro differentiation of bone marrow cells and cell
staining
Bone marrow-derived mononuclear cells (BMMCs) were
isolated from the femurs and tibias of B6 and TH mice and
cultured in DMEM supplemented with 10% fetal bovine serum
(FBS). After removal of floating cells, BMMCs were cultured
under osteogenic differentiation conditions for 8 days. Cells were
fixed and then stained with either alkaline phosphatase (ALP) or
tartrate-resistant acid phosphatase (TRAP) using a staining kit
according to the manufacturer’s instructions (Sigma-Aldrich, St.
Louis, MO, USA).
Reverse transcription and quantitative real-time PCR
analysis
Total RNA was isolated using TRIzol reagent (Gibco-BRL,
Invitrogen), followed by reverse transcription and real-time PCR
reactions using Superscript II (Invitrogen) and SYBR Green pre-
mix buffer and with an ABI-Prism 7700 sequence detector (Perkin-
Elmer Applied Biosystems, Foster City, CA, USA). Primers were
as follows: IL-6, 59-agttgccttcttgggactga-39,5 9- tccacgatttcccaga-
gaac-39; RANKL, 59-ctcttggtaccacgatcgag-39,5 9-aagccccaaagtacgt
cgca-39; OPG, 59-atgccgagagtgtagagaggat-39,5 9-aaacagcccagtg-
gaccattcct-39; OCN, 59-gcagcttggtgcacacctag-39,5 9-ggagctgctgtga-
catccat-39; IFN-c,5 9-agcaacagcaaggcgaaaa-39,5 9-ctggacctgtgggttg
ttga-39; IL-17, 59-gctccagaaggccctcaga-39,5 9-agctttccctccgcattga-
39; aromatase, 59-aaatgctgaaccccatgcag-39,5 9-aatcaggagaaggaggcc
cat-39; and b-actin, 59-agagggaaatcgtgcgtgac-39,5 9-caatagtgatgacc
tggccgt-39. Relative expression levels were calculated after nor-
malization to the level of b-actin.
ELISA/EIA
Cytokines such as IL-17, IFN-c, IL-6, and RANKL were
determined using ELISA kits (R&D systems, Minneapolis, MN,
USA). High-sensitivity ELISA/EIA kits were used to determine
the serum levels of leptin (Millipore. Billerica, MA, USA), OCN
(Biomedical Technologies, Inc., Stoughton, MA, USA), and OPG
(R&D Systems). Serum IL-6, IFN-c, and TGF-b were determined
using an ELISA Ready-SET-Go kit (eBioscience, Inc., San Diego,
CA, USA) and serum levels of testosterone and estradiol were
determined using EIA kits from Cayman chemical (Charlotte, NC,
USA).
Flow cytometry analysis
Single cell suspensions were collected from tissues and suspended
in FACS buffer (2% FBS in PBS). Cells were incubated with
fluorescence-conjugated antibodies against mouse CD4, CD8, Ly6C,
and RANKL (BD Pharmingen) followed by flow cytometry analysis
Figure 2. Imbalance of osteoblasts and osteoclasts in bone marrow of TH mice. (A) Total RNA was isolated from bone marrow cells of B6 and TH
mice at 8 weeks of age (n=6) and used for real time-PCR analysis. Relative expression levels of OCN, OPG, RANKL, and IL-6 were calculated after normalization
to the level of b-actin. (B) Culture supernatants were collected from bone marrow cells, and RANKL and IL-6 levels were determined by ELISA. (C) Bone marrow
cells were isolated and cultured for 24 h. After removal of floating cells, cells were maintained in DMEM supplemented with ascorbic acid (50 mg/ml), b-
glycerophosphate (2 mM) and dexamethasone (10 nM) for 8 days. Cells were fixed and stained with either ALP or TRAP.
doi:10.1371/journal.pone.0018168.g002
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intracellular cytokine staining, cells were pretreated with monensin
(4 mM) for 2 h before harvesting. Cells were fixed with 4%
paraformaldehyde solution, rinsed with permeabilization buffer
(0.1% saponin, 1% FBS in PBS), and then incubated with PE-
conjugated anti-IFN-c Ab (BD Pharmingen). Cell populations were
analyzed using CellQuest software (BD Biosciences).
Statistical analysis
The results are expressed as the mean 6 SEM. Statistical
significance was determined by one-way analysis of variance
(ANOVA) or two-tailed unpaired Student’s t-test. A P value less
than 0.05 was considered to be statistically significant for all
experiments.
Results
Bone density and bone mineral content (BMC) are
substantially decreased in TH mice
Since TH mice are known as a polygenic diabetes and obesity
model, we measured gains in body weight in B6 and TH mice fed
a normal diet. TH mice experienced significantly increases in body
weight compared to age-matched B6 mice during the examination
period (Fig. 1A). Although the body weights of male and female
TH mice were higher than those of age- and gender-matched B6
mice, BMD was substantially decreased in male TH mice but not
in female mice at ages of 8 and 12 weeks (Fig. 1B). Micro-CT
scanning also showed a considerable decrease in bone density in
TH mice at an age of 8 weeks (Fig. 1C). In addition, bone
mineralization was also significantly decreased in male TH mice
(Fig. 1D). Previous reports that male TH mice experience
increases in blood glucose levels with age and develop hypergly-
cemia, hyperleptinemia, and hyperinsulemia [31,32] are consistent
with our results and suggest that diabetic phenotypes may be
associated with bone loss in male TH mice.
Osteoblastogenic markers are decreased and
osteoclastogenic markers are increased in bone marrow
of TH mice
Attenuation of bone density in TH mice led us to examine the
expressionlevelsofosteoblast- and osteoclast-mediatedgene markers
in bone marrow cells. Osteoblast-specific OCN was significantly
decreased in both male and female TH mice compared to B6 mice,
whereas OPG was reduced in male TH mice but not in females
(Fig. 2A). Moreover, TH mice expressed higher levels of a bone
destruction mediating factor, RANKL, and a RANKL inducer, IL-
6,inbonemarrow.AlthoughfemaleTHmiceproducedsignificantly
higher levels of RANKL and IL-6 compared to B6 mice, these
increases were considerably lower in female than in male TH mice,
asevidenced byrealtime-PCRand ELISA(Fig. 2A andB). Next, we
isolated bone marrow cells and cultured the cells under osteoblast
differentiation conditions. Osteoblast-expressing ALP was clearly
detected in male and female B6 and TH mice, whereas giant
multinucleated osteoclasts clarified by TRAP staining were promi-
nently generated in TH mice (Fig. 2C). These results indicate that
TH mice expressed increased levels of the osteoclastogenic markers
RANKL and IL-6 and reduced amounts of OCN and OPG in bone
marrow, resulting in significant bone density loss.
Hyperleptinemia of TH mice is accompanied by
reduction of OCN and substantial increases in IL-6 and
IFN-c
Having confirmed the imbalance of osteoblasts and osteoclasts in
the bone marrow of TH mice, we further examined the serum levels
ofosteogenicfactors. Using the serumofmaleB6 and THmiceat an
Figure 3. Increased serum levels of leptin and inflammatory cytokines in TH mice. Whole blood was collected from mice (males, n=6) at 8 weeks
and used to measure the serum levels of leptin (A), OCN (B), OPG (C), IL-6 (D), IFN-c (E), and TGF-b (F). All data are expressed as the mean 6 SEM. P value was
calculated by student t-test.
doi:10.1371/journal.pone.0018168.g003
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osteoclastogenic factors such as cytokines and chemokines were
determined by ELISA. TH mice expressed substantially increased
amounts of leptin in serum compared to B6 mice, which was
consistent with the diabetic phenotype of TH mice (Fig. 3A). Serum
OCN expression was also significantly attenuated in TH mice,
whereas the reduction of serum OPG was not statistically significant
(Fig. 3B and C). Although RANKL expression in TH mice serum
was below thethreshold ofdetection ofELISA, serum IL-6andIFN-
c, both stimulators of RANKL expression, were statistically elevated
in TH mice (Fig. 3D and E). Additional analysis revealed that the
serum TGF-b level was unchanged in B6 and TH mice (Fig. 3F).
Based on the results, we suggest that increased serum levels of the
inflammatory cytokines IL-6 and IFN-c may cause RANKL-
induced bone loss in TH mice.
CD4+ T cells are increased in TH mice and associated
with increased IFN-c and IL-17 production
Increased levels of serum IL-6 and IFN-c in TH mice prompted
us to examine immune cell development in TH mice. A myeloid
marker, Ly6C, was prominently decreased in the bone marrow of
TH mice (Fig. 4A), which was consistent with a previous finding of
attenuated Ly6C expression in diabetes [33]. Further examination
of T cell development revealed that CD4+ T cells were increased
in the thymus and lymph node of TH mice when compared to B6
animals (Fig. 4B). In addition, stimulation of isolated CD4+ T cells
with anti-CD3 and anti-CD28 Abs for 24 h decreased IL-4 and
increased IFN-c expression in CD4+ T cells of TH mice (Fig. 4C).
Specifically, CD4+ T cells of TH mice produced more IFN-c than
those of B6 mice, as demonstrated by the addition of IL-12 with
anti-CD3/CD28 Abs (Fig. 4D and E). IL-4-producing CD4+ T
cells were significantly attenuated in TH mice in response to
exogenous IL-4 addition, whereas IFN-c-producing cells were
elevated (Fig. 4F). Moreover, stimulation of CD4+ T cells with
anti-CD3/28 Abs in the presence of TGF-b and IL-6 significantly
augmented IL-17 production in TH mice (Fig. 4G). Interestingly,
RANKL expression was significantly elevated in activated CD4+
T cells of TH mice compared to WT cells (Fig. 4H). These results
indicate that CD4+ T cells of TH mice were biased toward
differentiation into IFN-c- and IL-17-producing cells.
Figure 4. Altered CD4+ T cell functions in TH mice. All B6 and TH mice were analyzed at 8 weeks of age (n=8). (A) Bone marrow cells were
stained with fluorescence-conjugated anti-Ly6C Ab (BD Pharmingen) and analyzed using FACS Calibur and CellQuest program (BD Biosciences). (B)
Single cell suspensions of thymus and lymph node were harvested and stained with Abs against CD4 and CD8, followed by flow cytometry analysis.
(C) CD4+ T cells were isolated from the lymph node and stimulated with anti-CD3 and anti-CD28 for 24 h. Cells were then collected for real time-PCR
to determine the relative expression levels of IL-4 and IFN-c. (D-F) CD4+ T cells were stimulated for 48 h. IFN-c production was analyzed in the cell
supernatant by ELISA (D) and intracellular cytokine staining (E). (F) T cells were stained with anti-IFN-c and anti-IL-4 Abs (BD PHarmingen), followed by
flow cytometry. (G) T cells were stimulated and subsequently treated with TGF-b and IL-6 for 48 h. IL-17 was measured in the cell supernatant by
ELISA. (H) T cells were stimulated with anti-CD3/28 for 48 h, followed by incubation with anti-RANKL Ab and flow cytometry analysis.
doi:10.1371/journal.pone.0018168.g004
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responsible for enhanced RANKL expression in TH mice
Since TH mice produced a high amount of leptin and enhanced
RANKL expression in CD4+ T cells, we analyzed the direct
effects of leptin on the production of IFN-c and IL-17. Since leptin
directly suppresses regulatory T cell proliferation [34], CD4+ T
cells were stimulated with anti-CD3/28 Abs for 24 h and then
treated with or without leptin for an additional 24 h. Although
IFN-c production was not affected by leptin treatment, IL-17
production was significantly increased (Fig. 5A and B). Leptin
directly increased the gene transcription of IL-17 in CD4+ T cells
(Fig. 5C). We also assessed whether or not IFN-c affects RANKL
expression in CD4+ T cells. Treatment of CD4+ T cells with anti-
IFN-c Ab increased RANKL expression at the level of gene
transcription (Fig. 5D). Blockade of IFN-c signaling accelerated
IL-17 production in CD4+ T cells of TH mice but did not affect
IL-17 expression in B6 CD4+ T cells (Fig. 5E and F). We suggest
that the increased level of leptin in TH mice preferentially
increased IL-17 production and RANKL expression in CD4+ T
cells.
Reduced BMD in TH mice is restored by treatment with
alendronate
Since male TH mice exhibited a considerable bone loss as well as
hyperleptinemia, we investigated whether or not the testosterone
level changes in TH mice and if this hormone can restore the bone
density. First, we injected TH mice with testosterone and examined
its effects on bone density. Testosterone did not significantly increase
bone densityinTHmice,whereasbonelossinduced byorchiectomy
was restored bytheinjection of testosterone inbothB6 andTH mice
(Fig. 6A and B). Furthermore, serum testosterone levels as well as the
ratio of testosterone/estrogen were comparable between B6 and TH
mice (Fig. 6C). TH mice expressed similar amount of aromatase,
which convertstestosteroneto estradiol and is involved inthe control
of bone homeostasis (Fig. 6D), suggesting no hormonal defect in
osteoporotic TH males. On the other hand, decreased BMD in TH
mice was restored by administration with alendronate, which
reverses osteoporosis through the activation of osteoblasts and the
induction of osteoclast apoptosis (Fig. 6D). These results together
suggest that TH mice could be used as a model of secondary
osteoporosis to develop novel therapeutics for treating metabolic
bone diseases.
Discussion
In this study, we demonstrated that male TH mice as a
polygenic diabetes model developed an osteoporotic phenotype
with decreased bone density and increased osteoclastogenic
factors, such as IFN-c, IL-6, and RANKL, in the blood and bone
marrow. Moreover, RANKL was prominently increased in CD4+
T cells, which were biased towards differentiation into IL-17-
producing Th17 cells in TH mice. Treatment of leptin enhanced
IL-17 production in vitro.
TH mice have been characterized by hyperleptinemia, hyper-
insulemia, hyperlipidemia and male-specific hyperglycemia, and
they are established as a polygenic model for type II diabetes with
obesity [35]. Insulin deficiency or resistance as well as hyperglycemia
in patients with diabetes are known risk factors for metabolic bone
diseases, including osteoporosis [29]. Both leptin-deficient ob/ob
mice and leptin receptor-deficient db/db mice reveal increased
adiposity together with decreased BMD, suggesting an association
between adiposity and aberrant BMD [36,37]. Moreover, T cell
inflammation in the adipose tissue of these obese mice reveal
increased levels of TNF-a,I F N - c, or IL-6, resulting in dysregulation
of bone homeostasis [38–40]. Our results also demonstrate that male
TH mice with hyperglycemia and obesity underwent reduction of
BMD due to increased T cell inflammation. Although both female
Figure 5. Leptin-mediated IL-17 production in CD4+ T cells. CD4+ T cells were isolated from B6 mice (8 weeks, n=3) and stimulated with anti-
CD3/28 Ab for 24 h. (A-C) Leptin was added to the cells for an additional 24 h. Supernatant was used in ELISA for measurement of IFN-c (A) and IL-17
(B). Cells were used to determine the relative expression level of IL-17 by real time-PCR (C). (D-F) Stimulated CD4+ T cells were further treated with
either control (-aIFN-c) or anti-IFN-c Ab (+aIFN-c) for 24 h and then harvested to determine RANKL expression by real time-PCR (D). Culture
supernatants were used to measure the expression of IFN-c (E) and IL-17 (F) by ELISA.
doi:10.1371/journal.pone.0018168.g005
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locomotor activity [41], bone loss was specific to male TH mice.
Therefore, these results suggest that reduced locomotor activity has
no particular effect on BMD diminution in male TH mice. Reduced
bone density was the result of decreased levels of OCN and OPG,
increased RANKL expression, and high expression of IL-6 in TH
mice. Most of all, IL-6 expression was significantly elevated in male
TH mice, suggesting an important role for IL-6 in osteoporosis
development in male TH mice. IL-6 is critical for the induction of
CD4+ T cell differentiation into IL-17-producing T cells [42].
Consistently, TH mice produce a higher amount of IL-17 in
activated CD4+ T cells than in WT T cells, and this is well
associated with increased RANKL expression in T cells of TH mice.
Moreover, leptin directly induces IL-17 production, and blockade of
IFN-c further stimulates IL-17 production and RANKL expression
in CD4+ T cells of TH mice [43]. These observations suggest that
preferred IL-17 production by CD4+ T cells may increase RANKL-
mediated osteoclastic bone destruction in male TH mice.
Osteoporosis is one of the most common chronic bone diseases,
involving the progressive loss of bone density with age and sex
hormone deficiency. Although osteoporosis is more common in
women than men, several risk factors such as alcoholism, inflamma-
tory diseases, and hormonal disorders increase the incidence of
secondary osteoporosis in men [44]. In order to prevent and treat
osteoporosis, studies on the molecular mechanism of osteoporosis and
efficacies of new drugs have been performed using an ovariectomy- or
orchiectomy-induced osteoporosis model or a naturally aged SAMP-
6 (P6 substrain of senescence-accelerated mice) model [45]. However,
these methods are time-consuming and thus extremely costly. Our
study shows that TH mice may constitute an effective osteoporosis
model as it displays early onset of osteoporosis and male-specific
osteoporotic phenotype secondary to hyperglycemia. Moreover,
testosterone injection increased BMD in orchiectomized TH mice,
and treatment with alendronate restored BMD and BMC values of
TH mice to the levels of age-matched B6 mice. Therefore, we
propose that TH mice could be a useful animal model of secondary
osteoporosisfor the development ofnovel therapeutics that prevent or
treat bone loss and bone destruction in metabolic bone diseases.
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Figure 6. Restoration of BMD in TH mice by testosterone and alendronate. B6 and TH mice (n=6 each group) were orchiectomized at 8
weeks of age and subsequently injected with vehicle (sesame oil) or testosterone (50 mg/kg) for 6 weeks. (A) Micro-CT images of trabecular bone
were reconstructed, and one representative image is presented in each group. (B) BMD was calculated using a micro-CT scanner and micoView. All
results are expressed as the mean 6 SEM for 6 mice. (C) Serum testosterone levels of 8 week-old WT and TH mice (n= 5) were determined using a
high-sensitivity ELISA kit. The testosterone/estradiol ratio was determined after determination of serum estradiol level. (D) Relative expression level of
aromatase was quantitated in testis by real time PCR and normalization to the level of b-actin (n=4). (E) TH mice at 4 weeks of age (n=7) were orally
administered alendronate (ALD, 5 mg/kg/day) for 4 weeks. BMD and BMC were determined in B6 and TH mice at 8 weeks of age using a micro-CT
scanner.
doi:10.1371/journal.pone.0018168.g006
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